TriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale

Key Terms

gmp regulatory

Good Manufacturing Practice (GMP) is a set of regulatory standards and procedures that ensure products—especially medicines, medical devices, and related goods—are consistently made to meet safety, quality, and purity requirements. For investors, GMP compliance is like a factory’s hygiene and checklist system: it reduces the risk of product recalls, regulatory fines, and production stoppages, supports market access, and signals more reliable, lower-risk operations that can protect revenue and reputation.

rna therapeutics medical

RNA therapeutics are medicines that use snippets of genetic instructions called RNA to change what proteins cells make, either by turning off harmful proteins, restoring missing ones, or teaching cells to make new proteins. Investors care because these treatments can target diseases that were hard to treat before, offering potential for big revenues but also carrying development, manufacturing and regulatory risk similar to a software update that promises major new features but may take time and testing to work reliably.

rna polymerase medical

An enzyme that reads a cell’s DNA blueprint and builds RNA copies that tell the cell what proteins to make; think of it as a molecular copier that transcribes instructions from a library of DNA into working notes the cell can use. Investors should care because RNA polymerase activity is central to how therapies, vaccines and biotech manufacturing work, and it can be a target for drugs or a factor that affects production efficiency and regulatory risk.

dsrna medical

Double-stranded RNA (dsRNA) is a molecule made of two complementary RNA strands bound together, like two matching puzzle pieces forming a single structure. In biotech and drug development it matters because dsRNA can be the active ingredient that turns off specific genes or stimulates immune responses, so its presence affects a treatment’s mechanism, potential side effects, manufacturing complexity and regulatory scrutiny — all key factors for investors assessing risk and value.

nucleoside triphosphates medical

Nucleoside triphosphates are the molecular building blocks that cells use to make DNA and RNA and supply chemical energy for many biochemical reactions (ATP is the most familiar example). Think of them as both the letters in a genetic instruction manual and the batteries that power the copying and repair machinery. Investors care because these molecules are central to genetic tests, sequencing, drug development, and biologics manufacturing, so demand and cost can affect companies in those sectors.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

New Jupiter, FL facility enables RNA therapeutics developers to source critical manufacturing materials from a single, coordinated supplier, simplifying workflows and accelerating development timelines.

JUPITER, Fla.--(BUSINESS WIRE)-- TriLink, part of Maravai LifeSciences® (NASDAQ: MRVI), today announced the opening of its GMP enzyme manufacturing facility in Jupiter, Florida, designed to help RNA therapeutic developers simplify sourcing and scale production more efficiently. The facility supports a coordinated supply of key RNA manufacturing and IVT workflow materials from early research through commercial production.

The launch addresses a long-standing pain point for RNA therapeutics developers sourcing critical raw materials — enzymes, nucleotides, cap analogs, and tail technology — from multiple vendors with different quality systems, timelines, and points of contact. Managing different quality systems, timelines, and supply processes can slow development and create manufacturing risk. TriLink is now offering these materials as a coordinated, single-source package designed to simplify development and scale up.

The Jupiter facility was purpose-built for GMP enzyme manufacturing. It features controlled cleanroom environments, validated production processes, and scalable capacity designed to support both clinical-stage programs and commercial supply. Full traceability and quality systems are in place to meet regulatory requirements across major markets.

The facility is already supporting customer programs, with TriLink successfully shipping its first commercial GMP enzyme batch in June 2026. This milestone demonstrates the facility’s operational readiness and ability to provide commercial-scale supply of critical IVT raw materials to RNA therapeutics developers worldwide.

The facility’s flagship product is GMP CleanScribe™ RNA Polymerase that reduces double-stranded RNA (dsRNA) formation by up to 85% compared to standard Wild-type T7 RNA polymerases, a result demonstrated across internal and customer studies. dsRNA is a critical quality attribute in therapeutic mRNA manufacturing: its accumulation drives purification complexity, depresses final RNA purity, and increases immunogenicity risk in vivo. CleanScribe™ RNA Polymerase is engineered specifically for IVT workflows where controlling dsRNA at the synthesis step translates directly into downstream process efficiency and product quality.

An Integrated IVT Raw Materials Solution

TriLink BioTechnologies is now offering a coordinated supply of GMP-grade IVT raw materials:

• GMP CleanScribe™ RNA Polymerase Mix
• GMP NTPs (nucleoside triphosphates)
• GMP CleanCap® analogs — the industry-standard co-transcriptional capping reagents
• GMP ModTail™ technology — designed to enhance mRNA stability and in vivo protein expression

The integrated offering is designed to reduce vendor complexity, simplify tech transfer, and ensure material consistency across the development lifecycle from IND-enabling studies through BLA submission and commercial launch.

As RNA-based therapeutics move into later-stage clinical development and commercial production, reliable access to manufacturing materials becomes increasingly important. Enzyme performance variability, regulatory gaps in supplier quality systems, and multi-vendor logistics create compounding delays at precisely the stages when speed matters most.

Combining GMP manufacturing, high-performance enzyme design, and coordinated supply with TriLink’s other GMP consumables, is intended to compress this complexity into a single, accountable partner relationship.

“RNA therapeutics developers need reliable supply partners that can support them from early research through commercial manufacturing. By combining enzyme manufacturing capabilities with TriLink’s existing RNA technologies, we help customers simplify sourcing, reduce supply chain complexity, and accelerate scale-up with greater confidence.”

— Chad Decker, SVP Global Sales, TriLink BioTechnologies

To learn more about TriLink’s new GMP enzyme capabilities visit: https://www.trilinkbiotech.com/gmp-enzymes

About TriLink BioTechnologies

TriLink BioTechnologies, part of Maravai LifeSciences, is a global leader in nucleic acid technologies and manufacturing solutions for RNA therapeutics, vaccines, gene editing, and diagnostics. The company's portfolio includes modified nucleotides, mRNA products, proprietary technologies such as CleanCap® capping analogs and ModTail™ technology, and a growing portfolio of high-performance enzymes marketed under the Alphazyme brand. Supported by robust GMP manufacturing capabilities, TriLink enables customers from early-stage research through commercial production.

About Maravai LifeSciences

Maravai LifeSciences is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapies companies.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260616862149/en/

Investor Contact:
Deb Hart
Maravai LifeSciences
+1 858-988-5917
ir@maravai.com

Source: Maravai LifeSciences